vs
New Fortress Energy Inc.（NFE）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
New Fortress Energy Inc.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.6倍（$326.2M vs $207.3M），Ultragenyx Pharmaceutical Inc.净利率更高（-62.0% vs -259.7%，领先197.6%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -7.0%），Ultragenyx Pharmaceutical Inc.自由现金流更多（$-100.8M vs $-134.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -26.8%）
New Fortress Energy Inc.是一家全球能源基础设施企业，主要开发、持有并运营液化天然气进出口终端、天然气供应网络及低碳能源项目，服务美洲、加勒比地区客户，致力于提供低成本、低排放的能源解决方案。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
NFE vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $326.2M | $207.3M |
| 净利润 | $-847.1M | $-128.6M |
| 毛利率 | 35.5% | — |
| 营业利润率 | -193.0% | -54.7% |
| 净利率 | -259.7% | -62.0% |
| 营收同比 | -7.0% | 25.9% |
| 净利润同比 | -277.4% | 3.5% |
| 每股收益（稀释后） | $-3.03 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $326.2M | $207.3M | ||
| Q3 25 | $240.3M | $159.9M | ||
| Q2 25 | $228.1M | $166.5M | ||
| Q1 25 | $384.9M | $139.3M | ||
| Q4 24 | $350.7M | $164.6M | ||
| Q3 24 | $446.0M | $139.5M | ||
| Q2 24 | $291.2M | $147.0M | ||
| Q1 24 | $609.5M | $108.8M |
| Q4 25 | $-847.1M | $-128.6M | ||
| Q3 25 | $-263.0M | $-180.4M | ||
| Q2 25 | $-546.5M | $-115.0M | ||
| Q1 25 | $-175.4M | $-151.1M | ||
| Q4 24 | $-224.4M | $-133.2M | ||
| Q3 24 | $9.3M | $-133.5M | ||
| Q2 24 | $-88.9M | $-131.6M | ||
| Q1 24 | $54.1M | $-170.7M |
| Q4 25 | 35.5% | — | ||
| Q3 25 | 18.1% | — | ||
| Q2 25 | 8.4% | — | ||
| Q1 25 | 21.4% | — | ||
| Q4 24 | 17.6% | — | ||
| Q3 24 | 27.1% | — | ||
| Q2 24 | 23.8% | — | ||
| Q1 24 | 62.4% | — |
| Q4 25 | -193.0% | -54.7% | ||
| Q3 25 | -37.4% | -106.9% | ||
| Q2 25 | -170.3% | -64.8% | ||
| Q1 25 | -3.3% | -102.6% | ||
| Q4 24 | 65.0% | -74.3% | ||
| Q3 24 | 17.8% | -94.6% | ||
| Q2 24 | 12.3% | -79.1% | ||
| Q1 24 | 30.4% | -151.9% |
| Q4 25 | -259.7% | -62.0% | ||
| Q3 25 | -109.4% | -112.8% | ||
| Q2 25 | -239.6% | -69.0% | ||
| Q1 25 | -45.6% | -108.5% | ||
| Q4 24 | -64.0% | -80.9% | ||
| Q3 24 | 2.1% | -95.7% | ||
| Q2 24 | -30.5% | -89.5% | ||
| Q1 24 | 8.9% | -156.8% |
| Q4 25 | $-3.03 | $-1.28 | ||
| Q3 25 | $-0.96 | $-1.81 | ||
| Q2 25 | $-1.99 | $-1.17 | ||
| Q1 25 | $-0.65 | $-1.57 | ||
| Q4 24 | $-1.10 | $-1.34 | ||
| Q3 24 | $0.03 | $-1.40 | ||
| Q2 24 | $-0.42 | $-1.52 | ||
| Q1 24 | $0.23 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $226.5M | $421.0M |
| 总债务越低越好 | $8.2B | — |
| 股东权益账面价值 | $182.6M | $-80.0M |
| 总资产 | $10.6B | $1.5B |
| 负债/权益比越低杠杆越低 | 44.78× | — |
8季度趋势，按日历期对齐
| Q4 25 | $226.5M | $421.0M | ||
| Q3 25 | $145.2M | $202.5M | ||
| Q2 25 | $551.1M | $176.3M | ||
| Q1 25 | $447.9M | $127.1M | ||
| Q4 24 | $492.9M | $174.0M | ||
| Q3 24 | $90.8M | $150.6M | ||
| Q2 24 | $133.0M | $480.7M | ||
| Q1 24 | $143.5M | $112.3M |
| Q4 25 | $8.2B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $8.9B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $182.6M | $-80.0M | ||
| Q3 25 | $1.1B | $9.2M | ||
| Q2 25 | $1.3B | $151.3M | ||
| Q1 25 | $1.8B | $144.2M | ||
| Q4 24 | $1.9B | $255.0M | ||
| Q3 24 | $1.6B | $346.8M | ||
| Q2 24 | $1.6B | $432.4M | ||
| Q1 24 | $1.7B | $140.3M |
| Q4 25 | $10.6B | $1.5B | ||
| Q3 25 | $12.0B | $1.2B | ||
| Q2 25 | $12.0B | $1.3B | ||
| Q1 25 | $13.1B | $1.3B | ||
| Q4 24 | $12.9B | $1.5B | ||
| Q3 24 | $12.0B | $1.5B | ||
| Q2 24 | $11.4B | $1.6B | ||
| Q1 24 | $10.9B | $1.3B |
| Q4 25 | 44.78× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 4.74× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-76.2M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $-134.8M | $-100.8M |
| 自由现金流率自由现金流/营收 | -41.3% | -48.6% |
| 资本支出强度资本支出/营收 | 18.0% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.4B | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $-76.2M | $-99.8M | ||
| Q3 25 | $-171.0M | $-91.4M | ||
| Q2 25 | $-329.0M | $-108.3M | ||
| Q1 25 | $-7.2M | $-166.5M | ||
| Q4 24 | $445.3M | $-79.3M | ||
| Q3 24 | $-20.0M | $-67.0M | ||
| Q2 24 | $113.9M | $-77.0M | ||
| Q1 24 | $63.0M | $-190.7M |
| Q4 25 | $-134.8M | $-100.8M | ||
| Q3 25 | $-231.6M | $-92.7M | ||
| Q2 25 | $-726.7M | $-110.7M | ||
| Q1 25 | $-262.3M | $-167.8M | ||
| Q4 24 | $-210.3M | $-79.5M | ||
| Q3 24 | $-367.0M | $-68.6M | ||
| Q2 24 | $-493.2M | $-79.0M | ||
| Q1 24 | $-457.9M | $-193.9M |
| Q4 25 | -41.3% | -48.6% | ||
| Q3 25 | -96.4% | -58.0% | ||
| Q2 25 | -318.6% | -66.5% | ||
| Q1 25 | -68.2% | -120.5% | ||
| Q4 24 | -60.0% | -48.3% | ||
| Q3 24 | -82.3% | -49.2% | ||
| Q2 24 | -169.3% | -53.7% | ||
| Q1 24 | -75.1% | -178.2% |
| Q4 25 | 18.0% | 0.5% | ||
| Q3 25 | 25.2% | 0.8% | ||
| Q2 25 | 174.4% | 1.5% | ||
| Q1 25 | 66.3% | 1.0% | ||
| Q4 24 | 187.0% | 0.1% | ||
| Q3 24 | 77.8% | 1.2% | ||
| Q2 24 | 208.4% | 1.4% | ||
| Q1 24 | 85.5% | 3.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -2.15× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.16× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NFE
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
